2,2,3,3,4-Pentahydroxyhexanoic acid | 66664-08-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: 2,2,3,3,4-Pentahydroxyhexanoic acid
• CAS: 66664-08-2
• 化学式: C₆H₁₂O₇
• 分子量: 196.16
• InChiKey: SLSFSENIPXFAKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  138
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Methods for treating of skin conditions with retinoid double conjugate compounds
  申请人：US COSMECEUTECHS LLC

  公开号：US10123960B2

  公开（公告）日：2018-11-13

  A double conjugate molecule made of a retinoid, an organic acid, particularly an a-hydroxy acid, and an alcohol or acyl group, is provided which is useful in treating skin conditions, particularly aging. The retinoid, organic acid, and alcohol/acyl group are preferably linked via ester bonds.

  提供一种由视黄醇、有机酸（特别是α-羟基酸）和醇或酰基组成的双共轭分子，可用于治疗皮肤状况，特别是衰老。视黄醇、有机酸和醇/酰基组最好通过酯键连接。
• Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots.
  申请人：Van Scott, Eugene J., Dr.

  公开号：EP0273202A2

  公开（公告）日：1988-07-06

  Composition and method for enhancing therapeutic effects of topically applied agents are disclosed. The cosmetic or therapeutic composition may include one or more of cosmetic or pharmaceutical agents present in a total amount of from 0.01 to 40 percent and one or more of hydroxycarboxylic acids or related compounds present in a total amount of from 0.01 to 99 percent by weight of the total composition. The cosmetic and pharmaceutical agents may include but not limited to age spots, wrinkles and keratoses removing agents; vitamins; aloes; sun screens; tanning, depigmenting and shampooing agents; antiyeasts; antifungal, antibacterial and antiviral agents; topical bronchial dilators and topical cardiovascular agents; hormonal agents; vasodilators; retinoids and other dermatological agents. The hydroxycarboxylic acids and related compounds include organic alpha and beta hydroxycarboxylic acids, alpha and beta ketocarboxylic acids and salts thereof. Topical application of the cosmetic or therapeutic compostion has been found to achieve a substantial increase in cosmetic or therapeutic effect of the active ingredient in humans and domesticated animals.

  本发明公开了增强外用药剂治疗效果的组合物和方法。该化妆品或治疗组合物可包括一种或多种化妆品或药物制剂，其总量为组合物总重量的 0.01% 至 40%，以及一种或多种羟基羧酸或相关化合物，其总量为组合物总重量的 0.01% 至 99%。化妆品和药物制剂可包括但不限于老年斑、皱纹和角化去除剂；维生素；芦荟；防晒霜；美黑、脱色和洗发剂；抗酵母菌；抗真菌、抗细菌和抗病毒剂；局部支气管扩张剂和局部心血管制剂；激素制剂；血管扩张剂；维甲酸和其他皮肤病制剂。羟基羧酸及相关化合物包括有机 alpha 和 beta 羟基羧酸、alpha 和 beta 酮羧酸及其盐类。研究发现，局部施用美容或治疗复合剂可大幅提高活性成分对人类和驯养动物的美容或治疗效果。
• Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
  申请人：Yu, Ruey J., Dr.

  公开号：EP0413528A1

  公开（公告）日：1991-02-20

  Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatologic disorders in which the amphoteric compositions and the polymeric compounds may be useful include dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, kyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging, and skin requiring cleansers.

  本发明公开了含有α-羟基酸、α-酮酸、相关化合物或羟基酸聚合形式的两性组合物的预防和治疗方法，以缓解美容状况和皮肤病症状。两性组合物和聚合化合物可用于治疗的美容病症和皮肤病包括皮肤干燥、头皮屑、痤疮、角化病、牛皮癣、湿疹、瘙痒症、老年斑、色斑、黑斑、皱纹、疣、瑕疵皮肤、色素沉着皮肤、角化过度皮肤、炎症性皮肤病、与衰老有关的皮肤变化以及需要清洁剂的皮肤。
• Additives enhancing topical actions of therapeutic agents
  申请人：Van Scott, Eugene J., Dr.

  公开号：EP0770399A2

  公开（公告）日：1997-05-02

  Composition and method for enhancing therapeutic effects of topically applied agents are disclosed. The cosmetic or therapeutic composition may include one or more of cosmetic or pharmaceutical agents present in a total amount of from 0.01 to 40 percent and one or more of hydroxycarboxylic acids or related compounds present in a total amount of from 0.01 to 99 percent by weight of the total composition. The cosmetic and pharmaceutical agents may include but not limited to age spots, wrinkles and keratoses removing agents; vitamins; aloes; sun screens; tanning, depigmenting and shampooing agents; antiyeasts; antifungal, antibacterial and antiviral agents; topical bronchial dilators and topical cardiovascular agents; hormonal agents; vasodilators; retinoids and other dermatological agents. The hydroxycarboxylic acids and related compounds include organic alpha and beta hydroxycarboxylic acids, alpha and beta ketocarboxylic acids and salts thereof. Topical application of the cosmetic or therapeutic composition has been found to achieve a substantial increase in cosmetic or therapeutic effect of the active ingredient in humans and domesticated animals.

  本发明公开了增强外用药剂治疗效果的组合物和方法。该化妆品或治疗组合物可包括一种或多种化妆品或药物制剂，其总量为组合物总重量的 0.01% 至 40%，以及一种或多种羟基羧酸或相关化合物，其总量为组合物总重量的 0.01% 至 99%。化妆品和药物制剂可包括但不限于老年斑、皱纹和角化去除剂；维生素；芦荟；防晒霜；美黑、脱色和洗发剂；抗酵母菌；抗真菌、抗细菌和抗病毒剂；局部支气管扩张剂和局部心血管制剂；激素制剂；血管扩张剂；维甲酸和其他皮肤病制剂。羟基羧酸及相关化合物包括有机 alpha 和 beta 羟基羧酸、alpha 和 beta 酮羧酸及其盐类。研究发现，局部使用化妆品或治疗组合物可大大提高活性成分对人类和驯养动物的美容或治疗效果。
• Method for producing purified hematinic iron-saccharidic complex and product produced
  申请人：Chromaceutical Advanced Technologies, Inc.

  公开号：EP1719495A2

  公开（公告）日：2006-11-08

  A method for separating and purifying the active hematinic species present in iron-saccharidic complexes comprising sodium ferric gluconate complex in sucrose, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function, based on separation of the iron-saccharidic complex from one or more excipients and, preferably, lyophilization is disclosed. Separation of the iron-saccharidic complex permits its analytical quantification; further concentration or purification as a new and useful product; preparation of redesigned formulations for new and useful pharmaceuticals; and/or lyophilization. The ability to separate the iron-saccharidic complex responsible for hematinic function, including its lyophilized form, also provides a means for preparing analytical material to verify and validate its pharmacological integrity, patient safety and clinical performance, as well as analytical monitoring, standardization and quality control inspection over hematinic manufacturing processes and establishment of standards for use therewith.

  本发明公开了一种分离和纯化铁-糖络合物中的活性血红素的方法，铁-糖络合物包括蔗糖中的葡萄糖酸铁钠络合物、氢氧化铁-蔗糖络合物和糖酸铁络合物以及其他类似形式和功能的络合物，其基础是将铁-糖络合物从一种或多种赋形剂中分离出来，最好是冻干。铁-糖复合物的分离允许对其进行分析定量；进一步浓缩或纯化为新的有用产品；制备新的有用药物的重新设计配方；和/或冻干。能够分离具有造血功能的铁-糖复合物，包括其冻干形式，也为制备分析材料提供了一种方法，以验证和确认其药理完整性、患者安全性和临床表现，以及对造血剂生产过程进行分析监测、标准化和质量控制检查，并建立相关使用标准。